Work

PR029/#943 A phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator’s choice of therapy in patients with recurrent low-grade serous ovarian cancer: GOG-3097/ENGOT-ov81/NCRI/RAMP 301

Year: 2024

Type: article

Source: International Journal of Gynecological Cancer

DOI: 10.1136/ijgc-2024-igcs.71

Authors: Rachel Grisham, Bradley Monk, Els Van Nieuwenhuysen, Kathleen Moore, Michel Fabbro, David O’Malley, Ana Oaknin, Premal Thaker, Amit Oza, Nicoletta Colombo, Stephanie Lustgarten, Hagop Youssoufian, Susana Banerjee

Language: English

Topic: Ovarian cancer diagnosis and treatment

Subfield: Reproductive Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4403533763

FWCI:

Cites:

Cited by:

Related to: 10